BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, Raviglione M. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS. 2010;24 Suppl 5:S57-S65. [PMID: 21079430 DOI: 10.1097/01.aids.0000391023.03037.1f] [Cited by in Crossref: 52] [Cited by in F6Publishing: 63] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Tadesse Y, Gebre N, Daba S, Gashu Z, Habte D, Hiruy N, Negash S, Melkieneh K, Jerene D, K Haile Y, Kassie Y, Melese M, G Suarez P. Uptake of Isoniazid Preventive Therapy among Under-Five Children: TB Contact Investigation as an Entry Point. PLoS One 2016;11:e0155525. [PMID: 27196627 DOI: 10.1371/journal.pone.0155525] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
2 Melgar M, Shiraishi RW, Tende C, Mwanza S, Mulenga J, Khondowe S, Mwakazanga D, Kapungu K, Tembo M, Nota A, Lungu P, Moore B, Podewils LJ. Assessment of the tuberculosis case-finding and prevention cascade among people living with HIV in Zambia - 2018: a cross-sectional cluster survey. BMC Public Health 2021;21:859. [PMID: 33947361 DOI: 10.1186/s12889-021-10929-z] [Reference Citation Analysis]
3 Peters JA, Heunis C, Kigozi G, Osoba T, van der Walt M. Integration of TB-HIV services at an ANC facility in Frances Baard District, Northern Cape, South Africa. Public Health Action 2015;5:30-5. [PMID: 26400599 DOI: 10.5588/pha.14.0033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé JB, Carrou JL, Kouame GM, Ouattara E, Messou E, Anzian A, Minga A, Gnokoro J, Gouesse P, Emieme A, Toni TD, Rabe C, Sidibé B, Nzunetu G, Dohoun L, Yao A, Kamagate S, Amon S, Kouame AB, Koua A, Kouamé E, Daligou M, Hawerlander D, Ackoundzé S, Koule S, Séri J, Ani A, Dembélé F, Koné F, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatunde N, Bleoué G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Karcher S, Rouzioux C, Kouame A, Assi R, Bakayoko A, Domoua SK, Deschamps N, Aka K, N'Dri-Yoman T, Salamon R, Journot V, Ahibo H, Ouassa T, Menan H, Inwoley A, Danel C, Eholié SP, Anglaret X; Temprano ANRS 12136 Study Group. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health 2017;5:e1080-9. [PMID: 29025631 DOI: 10.1016/S2214-109X(17)30372-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 42] [Article Influence: 24.0] [Reference Citation Analysis]
5 Wyndham-Thomas C, Dirix V, Schepers K, Martin C, Hildebrand M, Goffard JC, Domont F, Libin M, Loyens M, Locht C, Van Vooren JP, Mascart F. Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube. BMC Infect Dis 2015;15:59. [PMID: 25886172 DOI: 10.1186/s12879-015-0796-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
6 Dirix V, Schepers K, Massinga-Loembe M, Worodria W, Colebunders R, Singh M, Locht C, Kestens L, Mascart F; TB-IRIS study group. Added Value of Long-Term Cytokine Release Assays to Detect Mycobacterium tuberculosis Infection in HIV-Infected Subjects in Uganda. J Acquir Immune Defic Syndr 2016;72:344-52. [PMID: 27306506 DOI: 10.1097/QAI.0000000000000980] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Swaminathan S, Menon PA, Gopalan N, Perumal V, Santhanakrishnan RK, Ramachandran R, Chinnaiyan P, Iliayas S, Chandrasekaran P, Navaneethapandian PD. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. PLoS One. 2012;7:e47400. [PMID: 23251327 DOI: 10.1371/journal.pone.0047400] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
8 Assebe LF, Reda HL, Wubeneh AD, Lerebo WT, Lambert SM. The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC Public Health 2015;15:346. [PMID: 25886730 DOI: 10.1186/s12889-015-1719-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
9 Bruins WS, van Leth F. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infect Dis (Lond) 2017;49:161-9. [PMID: 27911140 DOI: 10.1080/23744235.2016.1262059] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
10 Weldegebreal T, Ahmed I, Muhiye A, Belete S, Bekele A, Kaba M. Magnitude of opportunistic diseases and their predictors among adult people living with HIV enrolled in care: national level cross sectional study, Ethiopia. BMC Public Health 2018;18:820. [PMID: 29970047 DOI: 10.1186/s12889-018-5733-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Howard AA, Gasana M, Getahun H, Harries A, Lawn SD, Miller B, Nelson L, Sitienei J, Coggin WL. PEPFAR support for the scaling up of collaborative TB/HIV activities. J Acquir Immune Defic Syndr 2012;60 Suppl 3:S136-44. [PMID: 22797735 DOI: 10.1097/QAI.0b013e31825cfe8e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
12 Thit SS, Aung NM, Htet ZW, Boyd MA, Saw HA, Anstey NM, Kyi TT, Cooper DA, Kyi MM, Hanson J. The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study. BMC Med 2017;15:145. [PMID: 28774293 DOI: 10.1186/s12916-017-0888-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
13 Padmapriyadarsini C, Sekar L, Reddy D, Chitra A, Poornagangadevi N, Selvaraj M, Bhavani PK, Mothi SN, Nandagopal K, Vennila S, Tamizhselvan M, Maheshmanisha J, Agarwal U, Rewari BB, Swaminathan S. Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting. Indian J Med Res 2020;152:648-55. [PMID: 34145105 DOI: 10.4103/ijmr.IJMR_1582_18] [Reference Citation Analysis]
14 Teklay G, Teklu T, Legesse B, Tedla K, Klinkenberg E. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health 2016;16:840. [PMID: 27543096 DOI: 10.1186/s12889-016-3525-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
15 Cobelens FG. For whom the bell tolls: isoniazid preventive therapy and tuberculosis drug resistance. Sci Transl Med. 2013;5:180fs12. [PMID: 23576813 DOI: 10.1126/scitranslmed.3006094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Iroezindu MO, Ofondu EO, Mbata GC, van Wyk B, Hausler HP, Dh A, Lynen L, Hopewell PC. Factors Associated with Prevalent Tuberculosis Among Patients Receiving Highly Active Antiretroviral Therapy in a Nigerian Tertiary Hospital. Ann Med Health Sci Res 2016;6:120-8. [PMID: 27213096 DOI: 10.4103/2141-9248.181837] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
17 Sculier D, Getahun H, Lienhardt C. Improving the prevention, diagnosis and treatment of TB among people living with HIV: the role of operational research. J Int AIDS Soc 2011;14 Suppl 1:S5. [PMID: 21967874 DOI: 10.1186/1758-2652-14-S1-S5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
18 Hamada Y, Getahun H, Tadesse BT, Ford N. HIV-associated tuberculosis. Int J STD AIDS 2021;32:780-90. [PMID: 33612015 DOI: 10.1177/0956462421992257] [Reference Citation Analysis]
19 Kassa A, Jerene D, Assefa Y, Teka A, Aseffa A, Deribew A. Evaluation of collaborative TB/HIV activities in a general hospital in Addis Ababa, Ethiopia. BMC Res Notes 2012;5:67. [PMID: 22277087 DOI: 10.1186/1756-0500-5-67] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
20 Makanjuola T, Taddese HB, Booth A. Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data. PLoS One 2014;9:e87166. [PMID: 24498298 DOI: 10.1371/journal.pone.0087166] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
21 Tram KH, Mwangwa F, Chamie G, Atukunda M, Owaraganise A, Ayieko J, Jain V, Clark TD, Kwarisiima D, Petersen ML, Kamya MR, Charlebois ED, Havlir DV, Marquez C; SEARCH collaboration. Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda. AIDS Care 2020;32:119-27. [PMID: 31181961 DOI: 10.1080/09540121.2019.1619661] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Gopalan N, Chandrasekaran P, Swaminathan S, Tripathy S. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res Ther 2016;13:34. [PMID: 27708678 DOI: 10.1186/s12981-016-0118-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
23 Oni T, Tsekela R, Kwaza B, Manjezi L, Bangani N, Wilkinson KA, Coetzee D, Wilkinson RJ. A recent HIV diagnosis is associated with non-completion of Isoniazid Preventive Therapy in an HIV-infected cohort in Cape Town. PLoS One 2012;7:e52489. [PMID: 23285064 DOI: 10.1371/journal.pone.0052489] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
24 Kim HY, Hanrahan CF, Martinson N, Golub JE, Dowdy DW. Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa. Int J Tuberc Lung Dis 2018;22:1435-42. [PMID: 30606315 DOI: 10.5588/ijtld.18.0370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Ahmad Khan F, Verkuijl S, Parrish A, Chikwava F, Ntumy R, El-Sadr W, Howard AA. Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped. AIDS 2014;28:1463-72. [PMID: 24681417 DOI: 10.1097/QAD.0000000000000278] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
26 Maheswaran H, Barton P. Intensive case finding and isoniazid preventative therapy in HIV infected individuals in Africa: economic model and value of information analysis. PLoS One 2012;7:e30457. [PMID: 22291958 DOI: 10.1371/journal.pone.0030457] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
27 Aladesanmi AO, Ojuawo OB, Aladesanmi OO, Fawibe AE, Desalu OO, Ojuawo AB, Opeyemi CM, Adio MO, Oluwaloniola V, Salami AK. Diagnosis of latent tuberculosis among HIV infected patients in Ilorin, Nigeria using tuberculin skin test and interferon gamma release assay. Pan Afr Med J 2021;38:24. [PMID: 33777292 DOI: 10.11604/pamj.2021.38.24.24039] [Reference Citation Analysis]
28 Daftary A, Hirsch-Moverman Y, Kassie GM, Melaku Z, Gadisa T, Saito S, Howard AA. A Qualitative Evaluation of the Acceptability of an Interactive Voice Response System to Enhance Adherence to Isoniazid Preventive Therapy Among People Living with HIV in Ethiopia. AIDS Behav 2017;21:3057-67. [PMID: 27221743 DOI: 10.1007/s10461-016-1432-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
29 Jagger A, Reiter-Karam S, Hamada Y, Getahun H. National policies on the management of latent tuberculosis infection: review of 98 countries. Bull World Health Organ 2018;96:173-184F. [PMID: 29531416 DOI: 10.2471/BLT.17.199414] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
30 Sah SK, Sahu SK, Lamichhane B, Bhatta GK, Bhandari KB, Owiti P, Majumdar SS. Dotting the Three I's for collaborative TB-HIV activities: evaluation of a pilot programme in Kathmandu, Nepal. Public Health Action 2016;6:169-75. [PMID: 27695679 DOI: 10.5588/pha.16.0012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
31 Tiam A, Machekano R, Gounder CR, Maama-Maime LB, Ntene-Sealiete K, Sahu M, Isavwa A, Oyebanji O, Ahimbisibwe A, Mokone M, Barnes GL, Chaisson RE, Guay L, Kassaye S. Preventing tuberculosis among HIV-infected pregnant women in Lesotho: the case for rolling out active case finding and isoniazid preventive therapy. J Acquir Immune Defic Syndr 2014;67:e5-e11. [PMID: 25118796 DOI: 10.1097/QAI.0000000000000209] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
32 Telisinghe L, Amofa-Sekyi M, Maluzi K, Kaluba-Milimo D, Cheeba-Lengwe M, Chiwele K, Kosloff B, Floyd S, Bailey SL, Ayles H. The sensitivity of the QuantiFERON®-TB Gold Plus assay in Zambian adults with active tuberculosis. Int J Tuberc Lung Dis 2017;21:690-6. [PMID: 28482964 DOI: 10.5588/ijtld.16.0764] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
33 Yirdaw KD, Jerene D, Gashu Z, Edginton ME, Kumar AM, Letamo Y, Feleke B, Teklu AM, Zewdu S, Weiss B. Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia. PLoS One. 2014;9:e104557. [PMID: 25105417 DOI: 10.1371/journal.pone.0104557] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
34 Howard AA, Hirsch-Moverman Y, Saito S, Gadisa T, Daftary A, Melaku Z. The ENRICH Study to evaluate the effectiveness of a combination intervention package to improve isoniazid preventive therapy initiation, adherence and completion among people living with HIV in Ethiopia: rationale and design of a mixed methods cluster randomized trial. Contemp Clin Trials Commun 2017;6:46-54. [PMID: 28626811 DOI: 10.1016/j.conctc.2017.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
35 Catalani C, Green E, Owiti P, Keny A, Diero L, Yeung A, Israelski D, Biondich P. A clinical decision support system for integrating tuberculosis and HIV care in Kenya: a human-centered design approach. PLoS One 2014;9:e103205. [PMID: 25170939 DOI: 10.1371/journal.pone.0103205] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
36 Getahun H, Gunneberg C, Sculier D, Verster A, Raviglione M. Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services. Current Opinion in HIV and AIDS 2012;7:345-53. [DOI: 10.1097/coh.0b013e328354bd44] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
37 Buck WC, Nguyen H, Siapka M, Basu L, Greenberg Cowan J, De Deus MI, Gleason M, Ferreira F, Xavier C, Jose B, Muthemba C, Simione B, Kerndt P. Integrated TB and HIV care for Mozambican children: temporal trends, site-level determinants of performance, and recommendations for improved TB preventive treatment. AIDS Res Ther 2021;18:3. [PMID: 33422091 DOI: 10.1186/s12981-020-00325-9] [Reference Citation Analysis]
38 Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med 2019;380:1001-11. [PMID: 30865794 DOI: 10.1056/NEJMoa1806808] [Cited by in Crossref: 110] [Cited by in F6Publishing: 43] [Article Influence: 55.0] [Reference Citation Analysis]
39 den Boon S, Matteelli A, Getahun H. Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2016;20:1065-71. [PMID: 27393541 DOI: 10.5588/ijtld.15.0908] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
40 Lai J, Dememew Z, Jerene D, Abashawl A, Feleke B, Teklu AM, Ruff A. Provider barriers to the uptake of isoniazid preventive therapy among people living with HIV in Ethiopia. Int J Tuberc Lung Dis 2019;23:371-7. [PMID: 30871669 DOI: 10.5588/ijtld.18.0378] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
41 Al-Darraji HA, Kamarulzaman A, Altice FL. Latent tuberculosis infection in a Malaysian prison: implications for a comprehensive integrated control program in prisons. BMC Public Health 2014;14:22. [PMID: 24405607 DOI: 10.1186/1471-2458-14-22] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
42 Oliveira SM, Ruffino-Netto A, Paniago AM, Oliveira OA, Marques M, Cunha RV, Andreotti R. Tuberculin skin test: operational research in the state of Mato Grosso do Sul, Brazil. J Bras Pneumol 2011;37:646-54. [PMID: 22042397 DOI: 10.1590/s1806-37132011000500012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
43 Kim HY, Dowdy DW, Martinson NA, E Golub J, Bridges JFP, Hanrahan CF. Maternal priorities for preventive therapy among HIV-positive pregnant women before and after delivery in South Africa: a best-worst scaling survey. J Int AIDS Soc 2018;21:e25143. [PMID: 29972628 DOI: 10.1002/jia2.25143] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
44 Salazar-Austin N, Dowdy DW, Chaisson RE, Golub JE. Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration. Am J Epidemiol 2019;188:2078-85. [PMID: 31364692 DOI: 10.1093/aje/kwz172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
45 Roscoe C, Lockhart C, de Klerk M, Baughman A, Agolory S, Gawanab M, Menzies H, Jonas A, Salomo N, Taffa N, Lowrance D, Robsky K, Tollefson D, Pevzner E, Hamunime N, Mavhunga F, Mungunda H. Evaluation of the uptake of tuberculosis preventative therapy for people living with HIV in Namibia: a multiple methods analysis. BMC Public Health 2020;20:1838. [PMID: 33261569 DOI: 10.1186/s12889-020-09902-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Ousley J, Soe KP, Kyaw NTT, Anicete R, Mon PE, Lwin H, Win T, Cristofani S, Telnov A, Fernandez M, Ciglenecki I. IPT during HIV treatment in Myanmar: high rates of coverage, completion and drug adherence. Public Health Action 2018;8:20-4. [PMID: 29581939 DOI: 10.5588/pha.17.0087] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
47 Komba FF, Frumence G. Facility and patient barriers in the implementation of isoniazid preventive therapy for people living with HIV attending Care and Treatment Centers, Songea Municipality, Tanzania. Pan Afr Med J 2021;38:197. [PMID: 33995803 DOI: 10.11604/pamj.2021.38.197.26752] [Reference Citation Analysis]
48 Makoni A, Chemhuru M, Tshimanga M, Gombe NT, Mungati M, Bangure D. Evaluation of the isoniazid preventive therapy (IPT) program in Shurugwi District, Midlands Province, Zimbabwe, January 2013 to August 2014. BMC Res Notes 2015;8:476. [PMID: 26408193 DOI: 10.1186/s13104-015-1451-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
49 Cobelens F, van Kampen S, Ochodo E, Atun R, Lienhardt C. Research on implementation of interventions in tuberculosis control in low- and middle-income countries: a systematic review. PLoS Med 2012;9:e1001358. [PMID: 23271959 DOI: 10.1371/journal.pmed.1001358] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
50 Denegetu AW, Dolamo BL. Tuberculosis case finding and isoniazid preventive therapy among people living with HIV at public health facilities of Addis Ababa, Ethiopia: a cross-sectional facility based study. BMC Public Health 2014;14:52. [PMID: 24438508 DOI: 10.1186/1471-2458-14-52] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
51 Moolphate S, Lawpoolsri S, Pungrassami P, Sanguanwongse N, Yamada N, Kaewkungwal J. Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand. Glob J Health Sci 2013;5:60-70. [PMID: 23777722 DOI: 10.5539/gjhs.v5n4p60] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
52 Kim HY, Hanrahan CF, Dowdy DW, Martinson NA, Golub JE, Bridges JFP. Priorities among HIV-positive individuals for tuberculosis preventive therapies. Int J Tuberc Lung Dis 2020;24:396-402. [PMID: 32317063 DOI: 10.5588/ijtld.18.0740] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
53 Roy M, Muyindike W, Vijayan T, Kanyesigye M, Bwana M, Wenger M, Martin J, Geng E. Implementation and Operational Research: Use of Symptom Screening and Sputum Microscopy Testing for Active Tuberculosis Case Detection Among HIV-Infected Patients in Real-World Clinical Practice in Uganda. J Acquir Immune Defic Syndr 2016;72:e86-91. [PMID: 27159224 DOI: 10.1097/QAI.0000000000001067] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
54 Mueller Y, Mpala Q, Kerschberger B, Rusch B, Mchunu G, Mazibuko S, Bonnet M. Adherence, tolerability, and outcome after 36 months of isoniazid-preventive therapy in 2 rural clinics of Swaziland: A prospective observational feasibility study. Medicine (Baltimore) 2017;96:e7740. [PMID: 28858089 DOI: 10.1097/MD.0000000000007740] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
55 Zunza M, Gray DM, Young T, Cotton M, Zar HJ. Isoniazid for preventing tuberculosis in HIV-infected children. Cochrane Database Syst Rev 2017;8:CD006418. [PMID: 28850172 DOI: 10.1002/14651858.CD006418.pub3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
56 Wyndham-Thomas C, Schepers K, Dirix V, Mascart F, Van Vooren JP, Goffard JC. Implementation of latent tuberculosis screening in HIV care centres: evaluation in a low tuberculosis incidence setting. Epidemiol Infect 2016;144:703-11. [PMID: 26211466 DOI: 10.1017/S0950268815001594] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
57 Pathmanathan I, Ahmedov S, Pevzner E, Anyalechi G, Modi S, Kirking H, Cavanaugh JS. TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings. Int J Tuberc Lung Dis 2018;22:596-605. [PMID: 29862942 DOI: 10.5588/ijtld.17.0758] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
58 Ngugi SK, Muiruri P, Odero T, Gachuno O. Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study. BMC Infect Dis 2020;20:294. [PMID: 32664847 DOI: 10.1186/s12879-020-05011-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
59 Getahun H, Sculier D, Sismanidis C, Grzemska M, Raviglione M. Prevention, diagnosis, and treatment of tuberculosis in children and mothers: evidence for action for maternal, neonatal, and child health services. J Infect Dis 2012;205 Suppl 2:S216-27. [PMID: 22448018 DOI: 10.1093/infdis/jis009] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
60 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol 2015;4:105-12. [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
61 Yirdaw KD, Teklu AM, Mamuye AT, Zewdu S. Breakthrough tuberculosis disease among people with HIV - Should we be worried? A retrospective longitudinal study. PLoS One 2019;14:e0211688. [PMID: 30716126 DOI: 10.1371/journal.pone.0211688] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
62 Shapiro AE, van Heerden A, Schaafsma TT, Hughes JP, Baeten JM, van Rooyen H, Tumwesigye E, Celum CL, Barnabas RV. Completion of the tuberculosis care cascade in a community-based HIV linkage-to-care study in South Africa and Uganda. J Int AIDS Soc 2018;21. [PMID: 29381257 DOI: 10.1002/jia2.25065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
63 Getahun H, Matteelli A, Abubakar I, Hauer B, Pontali E, Migliori GB. Advancing global programmatic management of latent tuberculosis infection for at risk populations. Eur Respir J 2016;47:1327-30. [DOI: 10.1183/13993003.00449-2016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]